![Ben Goldacre on Twitter: "@NDevito1 @sebbacon Compliance with this law is very poor. But it is also *staying* poor: it is not improving over time. You can see for yourself in the Ben Goldacre on Twitter: "@NDevito1 @sebbacon Compliance with this law is very poor. But it is also *staying* poor: it is not improving over time. You can see for yourself in the](https://pbs.twimg.com/media/EOhhDJ_XkAAQxZB.jpg)
Ben Goldacre on Twitter: "@NDevito1 @sebbacon Compliance with this law is very poor. But it is also *staying* poor: it is not improving over time. You can see for yourself in the
![PDF) Transgelin: A New Gene Involved in LDL Endocytosis Identified by a Genome-wide CRISPR-Cas9 Screen PDF) Transgelin: A New Gene Involved in LDL Endocytosis Identified by a Genome-wide CRISPR-Cas9 Screen](https://i1.rgstatic.net/publication/348007092_Transgelin_A_New_Gene_Involved_in_LDL_Endocytosis_Identified_by_a_Genome-wide_CRISPR-Cas9_Screen/links/5ff0048e299bf1408864c14f/largepreview.png)
PDF) Transgelin: A New Gene Involved in LDL Endocytosis Identified by a Genome-wide CRISPR-Cas9 Screen
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase | Journal of Medicinal Chemistry
![Novartis teams up with smartpatient on new tool for patients with wet macular degeneration | MobiHealthNews Novartis teams up with smartpatient on new tool for patients with wet macular degeneration | MobiHealthNews](https://www.mobihealthnews.com/sites/default/files/Novartis%20app.png)
Novartis teams up with smartpatient on new tool for patients with wet macular degeneration | MobiHealthNews
![Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine](https://healthmagazine.ae/wp-content/uploads/2017/12/Psoriasis-Infographics-EN-1.jpg)
Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine
![Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1620925703/Ada-Health-Test.jpg?VersionId=EFmhfNYrjkc3gswzR2D4Bo4.oDg.zwO.)
Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech
![Eclipse and Mayo Clinic create Nucleus RadioPharma to better serve cancer patients - Mayo Clinic News Network Eclipse and Mayo Clinic create Nucleus RadioPharma to better serve cancer patients - Mayo Clinic News Network](https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2022/10/1613606_3867152_0035.jpg)
Eclipse and Mayo Clinic create Nucleus RadioPharma to better serve cancer patients - Mayo Clinic News Network
![H1, Which Operates A Healthcare Professional Network To Streamline Clinical Trials, Raises $100M To Accelerate Growth - CB Insights Research H1, Which Operates A Healthcare Professional Network To Streamline Clinical Trials, Raises $100M To Accelerate Growth - CB Insights Research](https://research-assets.cbinsights.com/2021/11/19045145/H1.png)
H1, Which Operates A Healthcare Professional Network To Streamline Clinical Trials, Raises $100M To Accelerate Growth - CB Insights Research
![How to Make/Create an Investment Summary [Templates + Examples] 2023 | Investing, Company financials, Book report templates How to Make/Create an Investment Summary [Templates + Examples] 2023 | Investing, Company financials, Book report templates](https://i.pinimg.com/originals/00/72/18/007218c9e16a8cbb7c7c32d7b8f2f417.png)
How to Make/Create an Investment Summary [Templates + Examples] 2023 | Investing, Company financials, Book report templates
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
![Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy | Science Advances Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy | Science Advances](https://www.science.org/cms/10.1126/sciadv.abl6339/asset/85c8b33a-1862-4d0c-9784-7abf7e9e0cbd/assets/images/large/sciadv.abl6339-f1.jpg)